Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck

被引：2
|
作者：
Kasi, Pashtoon Murtaza [1 ]
机构：
[1] Weill Cornell Med, Meyer Canc Ctr, Englander Inst Precis Med, 1305 York Ave, New York, NY 10021 USA
来源：
ONCOLOGIST | 2022年 / 27卷 / 05期
关键词：
D O I：
10.1093/oncolo/oyac070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：336 / 337
页数：2
相关论文
共 50 条
  • [21] Growth-factors system in anti-EGFR monoclonal antibody therapy in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
    Vladimirova, Liubov Yu
    Frantsiyants, Elena Mikhaylovna
    Engibaryan, Marina
    Agieva, Aza
    Cheryarina, Natalia D.
    Popova, Irina L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
    Altamura, Gennaro
    Borzacchiello, Giuseppe
    FRONTIERS IN VETERINARY SCIENCE, 2022, 9
  • [23] PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma
    van den Bossche, Valentin
    Vignau, Julie
    Vigneron, Engy
    Rizzi, Isabella
    Zaryouh, Hannah
    Wouters, An
    Ambroise, Jerome
    Van Laere, Steven
    Beyaert, Simon
    Helaers, Raphael
    van Marcke, Cedric
    Mignion, Lionel
    Lepicard, Elise Y.
    Jordan, Benedicte F.
    Guilbaud, Celine
    Lowyck, Olivier
    Dahou, Hajar
    Mendola, Antonella
    Desgres, Manon
    Aubert, Leo
    Gerin, Isabelle
    Bommer, Guido T.
    Boidot, Romain
    Vermonden, Perrine
    Warnant, Aurelien
    Larondelle, Yvan
    Machiels, Jean-Pascal
    Feron, Olivier
    Schmitz, Sandra
    Corbet, Cyril
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [24] A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study
    Klinghammer, K.
    Fayette, J.
    Kawecki, A.
    Dietz, A.
    Schafhausen, P.
    Folprecht, G.
    Rottey, S.
    Debourdeau, P.
    Lavernia, J.
    Jacobs, A.
    Ahrens-Fath, I.
    Dietrich, B.
    Baumeister, H.
    Zurlo, A.
    Ochsenreither, S.
    Keilholz, U.
    ESMO OPEN, 2021, 6 (05)
  • [25] CetuximabA Review of its Use in Squamous Cell Carcinoma of the Head and Neck and Metastatic Colorectal Cancer
    Stephanie K. A. Blick
    Lesley J. Scott
    Drugs, 2007, 67 : 2585 - 2607
  • [26] Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence
    Benson, Rony
    Mallick, Supriya
    Julka, P. K.
    Rath, G. K.
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2016, 28 (03) : 141 - 148
  • [27] Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Bhatia, Aarti
    Mehra, Ranee
    Bauman, Jessica
    Khan, Saad A.
    Wei, Wei
    Neumeister, Veronique
    Sandoval-Schaefer, Teresa
    Alpaugh, R. Katherine
    Lango, Miriam
    Rimm, David L.
    Ridge, John A.
    Burtness, Barbara
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,
  • [28] A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Dennis, Michael J.
    Sacco, Assuntina G.
    Qi, Yuchen
    Bykowski, Julie
    Pittman, Emily
    Chen, Ruifeng
    Messer, Karen
    Cohen, Ezra E. W.
    Gold, Kathryn A.
    ORAL ONCOLOGY, 2022, 135
  • [29] Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Seront, E.
    Schmitz, S.
    Rottey, S.
    Henry, S.
    Lonchay, C.
    van Caloen, G.
    Gilain, A.
    Machiels, J-P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report
    Gibson, M. K.
    Kies, M.
    Kim, S.
    Savvides, P.
    Kotsakis, A.
    Blumenschein, G.
    Worden, F.
    Chen, H.
    Grandis, J.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345